Furthermore, multiple FDA-approved inhibitors of CDK4/6 are already used in clinical practice, and the good clinical tolerability profiles of these drugs make them prime candidates for use in combination therapy, as exemplified by their current use in combination with hormonal therapy in estrogen receptor–positive breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.